Innovation often begins with questioning what everyone else accepts as inevitable. In hospitals, the relentless chorus of alarms and unpredictable infusion therapy have long been regarded as simply part of a standard healthcare experience. Jeffrey Carlisle saw something different: a set of problems that could be solved. Over the past five decades, the Founder and CEO of Pneuma Systems Corporation has pioneered new ways to transform how hospitals deliver infusion therapy, creating environments that are quieter, safer, and simpler for clinicians, patients, and their families.
A Career Built on Listening
Jeffrey did not set out to become an inventor. He studied Applied Mathematics and Biology, and his early career took him into the sales and marketing side of medical devices. But something happened along the way that redirected him entirely. He describes it simply as being pulled by “the voice of the customer,” a phrase that turns out to be less a slogan than a genuine account of how his mind works. Rather than accepting what already existed on the market, he found himself drawn repeatedly to what could be improved. Ironically, Jeffrey has struggled with hearing loss his entire life, yet considers listening to be key to his success.
That pull proved irresistible. Though he had no formal engineering training, Jeffrey became, in his words, intensely involved in the technical details behind medical devices, including electronics, mechanical design, fluidics, and software. It was while still working as a sales representative for Harvard Apparatus that he designed and patented his first device, a hybrid infusion pump and controller. It was an unlikely origin for a career, a patent filed by a man whose job title said nothing about engineering.
From there, the path moved quickly. At Hewlett-Packard’s medical group, he led the introduction of the PageWriter, an electrocardiograph design that was, by all accounts, highly disruptive. He was then recruited to lead Bard Electrophysiology, a company later sold to Boston Scientific, where he pioneered work in treating tachyarrhythmias through cardiac mapping and ablation.
His career then carried him into the orbit of one of the most famous inventors in America. At Dean Kamen’s DEKA, he oversaw the development of a peritoneal dialysis device, work that eventually resulted in Baxter’s HomeChoice system. It is the kind of credential that might have satisfied most engineers for a lifetime. For him, it was simply another chapter.
The Ventures That Came Before Pneuma
Seeing that infusion therapy still held unmet needs, Jeffrey founded FluidSense. The company launched a product later adopted by HCA and recognized as Time Magazine’s Product of the Year, an honor that speaks to the ambition and originality of the work. But timing, as it so often does in business, intervened. FluidSense failed to secure the capital it needed amid the collapse of the DotCom boom and the economic aftermath of September 11, 2001.
Rather than retreat, he built again. He created Fluidnet, later renamed Ivenix, a company that was eventually sold to Fresenius and that continues to enjoy market success. It is a detail worth sitting with. Not every founder gets to see an earlier creation thrive under someone else’s stewardship. He has watched it happen more than once.
Why Pneuma Systems Exists
By the time Jeffrey arrived at the idea for Pneuma, he had already tried, more than once, to solve the problems of infusion therapy. And still he wasn’t satisfied. Existing devices, in his assessment, remained too complex, too expensive, and demanded too much nurse training simply to be operated safely. It is the kind of dissatisfaction that either ends a career or launches a new one.
For Jeffrey, it launched a new one. The origin of Pneuma’s core technology has an almost accidental quality to it, the sort of discovery story that engineers tend to tell with a touch of wonder. While experimenting with automated laboratory pipetting systems, he came across a pneumatic technology that intrigued him. It needed additional elements to become useful, so he collaborated with Minivalve, a company based in the Netherlands, to invent novel fluid control elements. From there, Pneuma formed a partnership with a company that produces mission-critical components for aeronautics and space exploration, chosen specifically because of the uncompromising reliability standards those industries demand.
Driven by continual feedback from the people who use these devices, Pneuma has developed more than 30 inventions, culminating in an infusion platform that he describes as elementally simple. For the first time, the platform measures volume, flow, impedance, and more within a unified system. The result, he says, is a level of reliability that ensures the system rarely fails and never fails “unknowingly.”
What the Industry Gets Wrong
Ask Jeffrey what troubles him most about the current state of IV therapy, and the answer arrives without hesitation. He believes market leaders have been constrained by their own success, comfortable within the profitability of long-standing designs, which has limited genuine innovation in how fluid is delivered to patients. He also points to a more subtle problem: many healthcare buyers still focus primarily on the lowest cost of individual items rather than the overall cost of therapy.
That total cost, in his framing, includes far more than the price tag on a pump. It includes the cost of the drug itself, the labor of preparing it, nursing time, biomedical engineering support, disinfection, and, he insists, most importantly, the cost of patient harm.
He is similarly candid about the limitations of so-called smart pump technology, which has expanded steadily over the past two decades. That expansion has come with substantial cost and added burden to clinical workflows, and he asks two pointed questions in return: have “smart pumps” meaningfully reduced harm, and is there a simpler, lower-cost, and more effective way to reduce drug programming errors? These are not rhetorical flourishes. They appear to be the questions that guide Pneuma’s entire product philosophy.
Looking forward, he sees connectivity, artificial intelligence, and modern digital tools as fundamental to where Pneuma is headed. He also speaks with particular emphasis about continuity of care, the idea that infusion systems must function seamlessly across a patient’s entire journey, from emergency treatment in the field, through various hospital departments, including MRI suites, to standalone infusion centers, and eventually into the home. Throughout that journey, he insists, the patient must remain the focal point of design.
Building Something Genuinely Different
Pneuma’s approach, as Jeffrey describes it, begins with understanding unmet needs directly from the people closest to the problem: nurses, patients, pharmacists, and biomedical engineers. Because the infusion market is dominated by a small number of very large companies, he believes Pneuma cannot succeed with a modest, incremental improvement. It must offer something genuinely disruptive.
That philosophy extends into how the company thinks about its own business. He is careful to note that Pneuma’s marketing strategy is not simply about selling pumps and sets. Instead, the company aims to collaborate with healthcare providers to improve the entire infusion process, including how fluid moves, how information is conveyed, and how workflow functions, which means pricing, service, and support must all be reconsidered from the ground up.
The Discipline of Simplicity
If there is a single thread that runs through Jeffrey’s decades of work, it is a devotion to simple, closed-loop control systems. He is candid about a pattern observed across most design processes: that initial ideas tend to grow more complex over time, almost by default. Pneuma’s discipline, as he describes it, is to continuously push back against that tendency, remove clutter from user interfaces, eliminate unnecessary mechanical parts, and build software state machines that are unambiguous, testable, and require fewer lines of code.
Simplicity, in his view, is directly tied to reliability. But he draws a careful distinction; failures must never be unknown. Pneuma calls this principle coherence testing, a system in which every action within the device can be observed independently, so that nothing happens invisibly.
That same philosophy governs how Pneuma approaches measurement. His reasoning is almost mathematical in its clarity: if you control fluid delivery, you should measure it. Some infusions require a steady rate, which means flow must be measured. Others require a precise dose delivered over time, which means volume must be measured. And every infusion depends on a good connection to the patient, which means patient line resistance must be measured as well. He states plainly that no infusion device currently on the market performs all of these measurements together, a claim that positions Pneuma’s platform as something genuinely distinctive.
Leading a Small, Deliberate Team
As CEO, Jeffrey describes his responsibilities in two parts: inventing and securing the resources and alignment needed to keep development and operational partners moving toward the same mission. Regulatory work, he insists, should never be treated as a separate hurdle bolted onto product development. At Pneuma, regulatory requirements are treated as a subset of the company’s own internal expectations, not obligations to be satisfied after the fact.
That philosophy appears to be paying dividends. He speaks with evident pride about Pneuma’s acceptance into the FDA’s Safer Technologies Program (STeP), an expedited development, assessment, and review pathway reserved for technologies with meaningful safety potential.
Pneuma itself remains intentionally small, a team of experienced professionals spanning R&D, intellectual property, manufacturing, regulatory affairs, sales, marketing, and clinical support. He believes the company’s real competitive advantage is not technology alone, but what he calls “referent knowledge,” a depth of practical, hard-won expertise that ensures Pneuma is never in a second-place position when meeting with market leaders.
Standing Up to an Entrenched Market
Entering a market dominated by long-established incumbents is never simple, and Jeffrey does not pretend otherwise. He describes facing resistance from those incumbents, along with investor hesitation rooted in the regulatory difficulty of medical devices, the inherent risk of the category, and a lingering skepticism that a highly innovative product might simply be too challenging to bring to market.
Pneuma’s answer to that resistance has been to remain independent and to follow a crawl-walk-run strategy, building trust through early clinical collaboration and repeatedly measuring results before scaling further. It is a patient approach in an industry that does not always reward patience.
A Philosophy Built Over Fifty Years
Jeffrey remains convinced that infusion therapy still holds significant unmet needs, and he expects the integration of networking and artificial intelligence to open further opportunities in the years ahead. His leadership philosophy, distilled from decades of building and rebuilding, is consistent: start with purpose, iterate frequently, fail often, and continually challenge the work in front of you to simplify it further.
He expressed his views on the creative process in a book entitled “WE LOVE INNOVATION, so long as it’s nothing new”. He also chooses to surround himself with people he genuinely likes and respects. In the end, he frames the entire pursuit, including its detours and setbacks, as the journey itself, and he encourages the people around him to enjoy the process of taking it.
Quotes
